March 1, 2012
Last week, scientists from the Covance Biomarker Center of Excellence along with other business units in the Discovery and Translational Services group attended the Molecular Med-Tri-Con meeting in San Francisco to discuss Covance R&D capabilities, talent and technologies.
The Molecular Med Tri-Con is an annual conference that brings together the therapeutic and diagnostic aspects of the life sciences industry. Over 3,000 delegates from 1,200 companies engaged in interactive lectures, discussions, and various receptions on diagnostics, drug discovery and development, informatics and cancer.
Walter Jessen, Ph.D., Computational Biologist with the Covance Biomarker Center of Excellence, presented a poster entitled "Mining PubMed for Biomarker-Disease Associations to Guide Discovery." The poster illustrates an informatics strategy to guide biomarker discovery by identifying therapeutic areas with candidate or validated biomarkers.
After mining PubMed for biomarker-disease associations and curating the top 100 results, researchers used Covance BioPathways, an online data resource that maps validated Covance assays and antibody products to biological and disease pathways, to identify commercially available biomarker assays. The poster below shows two examples of the approach: first for atherosclerosis and second for asthma.
For a high-resolution PDF of the poster, please e-mail: firstname.lastname@example.org
Covance provides high-performance scientific computing and analysis support throughout the drug development pipeline, from early stage preclinical discovery to late stage clinical development. See the Covance Computational Biology page for more information on the services offered.
BCOE News Archive